Bifidobacterium Probiotic Administration for Atopic Disease Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis in infants are ineffective in completely curing the condition, and there is a need for methods to prevent, delay, or ameliorate the onset of atopic diseases such as atopic dermatitis, food allergy, allergic rhinitis, and asthma in breastfed infants, particularly those with a family history of atopic diseases.
Innovation Solution
Administering a composition comprising an effective amount of Bifidobacterium, specifically strains like B. infantis, to breastfed infants, either mixed with breastmilk or infant formula, to promote immunoregulation and colonize the gut, thereby reducing the risk of atopic disease onset.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical treatments (lotions, ointments) are used to treat atopic dermatitis, then symptomatic relief is provided, but the disease cannot be completely cured and requires ongoing treatment
Solution Approach 1:
The patent applies preliminary action by administering Bifidobacterium probiotics to infants during the critical early period of immune system development (first year of life), particularly to those with family history of atopic diseases. This preventive intervention aims to establish proper gut microbiota colonization before atopic diseases develop, thereby preventing the need for long-term symptomatic treatment. The probiotic administration occurs during the window of opportunity when the immune system is still maturing and can be positively influenced.
2Reliability
If probiotics are administered to prevent atopic diseases, then disease onset may be prevented or delayed, but the mechanism of action and optimal administration parameters require determination
Solution Approach 1:
The patent applies parameter changes by systematically determining and optimizing key administration parameters including: specific Bifidobacterium strains (e.g., B. infantis, B. longum, B. breve), dosage amounts (5-10 billion CFU daily), administration timing (within first year of life, preferably first 6 months), and delivery methods (mixed with breastmilk, formula, or water). These optimized parameters maximize prevention effectiveness while simplifying the administration protocol to a straightforward daily probiotic supplement regimen.
3Ease of operation
If Bifidobacterium is mixed with breastmilk or formula for administration, then infant compliance is improved, but the composition stability and bacterial viability during mixing and storage must be maintained
Solution Approach 1:
The patent applies the intermediary principle by using breastmilk or infant formula as a gentle, biocompatible delivery medium that is already familiar to the infant's digestive system. The probiotics are mixed with these liquids immediately before administration rather than being stored long-term in them, minimizing exposure to conditions that could compromise bacterial viability. The warm temperature of freshly expressed breastmilk or prepared formula (when not overheated) provides a suitable environment for probiotic survival during the brief mixing and administration process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of Bifidobacterium strains like B. infantis has shown potential in reducing the incidence and severity of atopic dermatitis and other atopic diseases by promoting a healthy gut microbiome, improving infantile colic, sleep, and anthropometrics, and potentially delaying the onset of these conditions in high-risk infants.
Implementation Method 1
administering a composition comprising an effective amount of a Bifidobacterium... to promote immunoregulation and colonize the gut
Implementation Method 2
administering a composition comprising an effective amount of a Bifidobacterium... to promote immunoregulation
Data Source
AI summary
Provided are compositions methods of preventing, delaying or ameliorating atopic dermatitis in a breastfed infant having an increased risk of developing an atopic disease, the method comprising administering a composition comprising administering a Bifidobacterium to the breastfed infant.